Pfizer and BioNTech have applied to US regulatory authorities for emergency authorisation of a Covid-19 vaccine specifically tailored to target the most dominant strain of the Omicron variant ahead of a nationwide booster programme planned for the autumn.
辉瑞(Pfizer)和BioNTech已向美国监管机构申请紧急批准一款新冠疫苗，该疫苗专门针对Omicron变体的最主要毒株。美国计划今年秋季在全国范围内实施一项加强针计划。
您已阅读9%（344字），剩余91%（3287字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。